HomeBusinessCipla receives a warning letter from USFDA for its Goa manufacturing unit

Cipla receives a warning letter from USFDA for its Goa manufacturing unit

Date:

Trending

- Advertisement -
Advertise During Budget
Advertise During Budget
Advertise During Budget
Advertise During Budget

The US Food and Drug Administration (USFDA) has issued a warning letter to Cipla’s Goa manufacturing facility.

In a regulatory filing with Stock Exchange, the company said, “Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019, by the US Food and Drug Administration (USFDA), the company has received a warning letter from USFDA.”

- Advertisement -

“It is committed to maintaining high standards of compliance and will work closely with the agency to comprehensively address all the observations,” the filing said.

THE SNAPSHOTS, IN YOUR INBOX

Get quick snaps of everyday happening, directly in your inbox.

We don’t spam! Read our privacy policy for more info.

- Advertisement -
Krishna Mali
Krishna Mali
Founder, CEO & Group Editor of TechGraph.
spot_img

More Latest Stories

Related Stories